Microbiotica
Microbiotica develops oral medicines made from selected live bacteria for inflammatory diseases and cancer treatment.
£36MSeries C first close
ParticipantCI
Cambridge Innovation Capital
Activity from announced rounds
Activity in this selectionSeries C+
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- — 0 disclosed · full round size, not this investor’s share